Clinical Orthopaedics and Related Research: November 2011 - Volume 469 - Issue 11 - p 3164–3171 doi: 10.1007/s11999-011-1938-3 Clinical Research

Cementless Revision TKA with Bone Grafting of Osseous Defects Restores Bone Stock with a Low Revision Rate at 4 to 10 years

Hanna, S., A., MRCS1, a; Aston, W., J. S., FRCS (Orth)1; de Roeck, N., J., FRCS (Orth)2; Gough-Palmer, A., FRCR3; Powles, D., P., MD, FRCS2
Knee

Background Addressing bone loss in revision TKA is challenging despite the array of options to reconstruct the deficient bone. Biologic reconstruction using morselized loosely-packed bone graft potentially allows for augmentation of residual bone stock while offering physiologic load transfer. However it is unclear whether the reconstructions are durable.

 

Questions/purposes We therefore sought to determine (1) survivorship and complications, (2) function, and (3) radiographic findings of cementless revision TKA in combination with loosely-packed morselized bone graft to reconstruct osseous defects at revision TKA.

 

Patients and Methods We retrospectively reviewed 56 patients who had undergone revision TKAs using cementless long-stemmed components in combination with morselized loose bone graft at our institution. There were 26 men and 30 women with a mean age of 68.3 years (range, 56-89 years). Patients were followed to assess symptoms and function and to detect radiographic loosening, component migration, and graft incorporation. The minimum followup was 4 years (mean, 7.3 years; range, 4-10 years).

 

Results Cumulative prosthesis survival, with revision as an end point, was 98% at 10 years. The mean Oxford Knee Scores improved from 21 (36%) preoperatively to 41 (68%) at final followup. Five patients (9%) had reoperations for complications.

 

Conclusions Our observations suggest this technique is reproducible and obviates the need for excessive bone resection, use of large metal augments, mass allografts, or custom prostheses. It allows for bone stock to be reconstructed reliably with durable midterm component fixation.

 

Level of Evidence Level IV, therapeutic study. See Guidelines for Authors for a complete description of levels of evidence.


Link to article